Preterm infants
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Preterm infants less than 32 weeks of gestation or very low birth weight infants less than 1,500g 2) Children aged 6 years or older and 9 years or younger at the time of obtaining consent 3) Children receiving outpatient care 4) Children attending regular nursery schools, kindergartens, or elementary schools 5) Children who have written consent from a legal representative 6) Children who the principal investigator (subinvestigator) judges to be able to appropriately evaluate the efficacy and safety of this study after considering the inclusion and exclusion criteria
Exclusion criteria
Exclusion criteria: 1) Children with mental or motor development problems who are unable to safely take the chewable tablets used 2) Children who are unable to take chewable tablets 3) Children taking NMN as a supplement 4) Children undergoing treatment for other diseases 5) Children who the principal investigator (subinvestigator) considers inappropriate as study subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety evaluation (occurrence of side effects in children related to NMN intake and duration of clinical test results) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Blood NAD concentration (Changes from before administration to the end of NMN administration) 2) Changes in body size (BMI, obesity level, fat mass, body fat percentage, fat-free mass, lean mass index) (Changes from before administration to the end of NMN administration) 3) Insulin resistance evaluation (blood glucose level, insulin level, HOMA-IR) (Changes from before administration to the end of NMN administration) 4) Urinary oxidative stress marker (8-OHdG level) (Changes from before administration to the end of NMN administration) | — |
Contacts
Juntendo University, Juntendo hospital